Insulet (NASDAQ:PODD) Price Target Lowered to $210.00 at Piper Sandler

Insulet (NASDAQ:PODD) had its price target reduced by research analysts at Piper Sandler from $360.00 to $210.00 in a report released on Wednesday,MarketScreener reports. Piper Sandler’s price objective indicates a potential upside of 33.35% from the company’s current price.

A number of other analysts have also recently commented on the company. Leerink Partners reduced their price objective on Insulet from $360.00 to $247.00 in a research report on Thursday. Jefferies Financial Group lowered their price objective on shares of Insulet from $400.00 to $360.00 in a research note on Thursday. Evercore cut their target price on shares of Insulet from $240.00 to $200.00 in a research report on Thursday. Weiss Ratings upgraded shares of Insulet from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Finally, Stifel Nicolaus cut their price objective on shares of Insulet from $350.00 to $250.00 in a research report on Thursday. Eighteen analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $263.91.

Insulet Stock Performance

Shares of PODD traded up $6.20 during mid-day trading on Wednesday, hitting $157.48. 81,593 shares of the company traded hands, compared to its average volume of 1,069,567. The stock has a market cap of $10.91 billion, a price-to-earnings ratio of 44.72, a P/E/G ratio of 0.99 and a beta of 1.20. The stock has a 50-day moving average price of $212.92 and a two-hundred day moving average price of $264.96. Insulet has a 1 year low of $148.30 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The firm’s revenue was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts anticipate that Insulet will post 6.27 earnings per share for the current year.

Insider Activity

In other news, Director Michael R. Minogue acquired 2,030 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the transaction, the director directly owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.36% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Insulet

A number of institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC raised its holdings in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. bought a new position in shares of Insulet in the fourth quarter worth about $26,000. Elyxium Wealth LLC purchased a new stake in shares of Insulet during the fourth quarter worth about $28,000. DV Equities LLC purchased a new stake in shares of Insulet during the fourth quarter worth about $28,000. Finally, MV Capital Management Inc. bought a new stake in Insulet during the 4th quarter valued at approximately $29,000.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 results beat expectations — EPS $1.42 vs. ~$1.19 consensus and revenue $761.7M (+33.9% Y/Y), driven by strong Omnipod demand. This confirms solid top-line momentum. Insulet Reports First Quarter 2026 Results
• Positive Sentiment: Company raised its annual revenue growth outlook after the quarter, citing sustained demand for its tubeless insulin pumps — a supportive signal for medium-term sales trajectory. Insulet lifts annual revenue forecast after quarterly beat
• Neutral Sentiment: Earnings call commentary was broadly upbeat (Omnipod growth emphasized) and management provided slide materials/transcripts for investors to parse execution details. These materials clarify drivers but don’t change the headline beat. Q1 2026 Earnings Call Transcript
• Negative Sentiment: FY 2026 EPS guidance appears below some Street estimates (company set FY EPS around ~6.21 vs. ~6.33 consensus cited by analysts), which likely disappointed investors despite the revenue upgrade. Earnings and guidance details
• Negative Sentiment: BTIG cut its price target from $320 to $260 (still a Buy rating); the PT reduction signals some analyst re?valuation and may have amplified selling pressure. BTIG price target cut

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.